Charles River Laboratories International, Inc. CRL | NYSE
Company Overview:
10 Year CRL Performance Metrics:
Unlock All Reports & Research Dividend Stocks like a BOSS!
CRL Earnings, Revenue, Cash & Debt, Shares Outstaning:
Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:
Ratios, Profit Margins & Return on Capital:
Projected Future Returns & Dividends for CRL
Based on past 10-year performance, here are CRL growth metrics:
Share price CAGR of +7.64%
Dividend CAGR of +0%
Using CRL CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, should grow as follows:
| CRL (DRIP) | CRL - No DRIP | |
|---|---|---|
| Current Price | $151.95 | $151.95 |
| Start Shares | 65.81 | 65.81 |
| Start Value | $10,000 | $10,000 |
| After 10 years: | ||
| Final Share Count | 65.81 | 65.81 |
| Dividends Payment | $0.00 | $0.00 |
| Annual Dividends | $0 | $0 |
| Yield on cost | 0.00% | 0.00% |
| Share Price | $294.65 | $151.95 |
| Total Dividends | $0 | $0 |
| Final Value | $19,392 | $10,000 |
NOTE: Above numbers are our estimate based on CRL's Dividend and Price CAGR over past 10 years.
These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.
We cannot guarantee that your actual returns will meet these estimates.
Get the best Dividend Stock Research Tools:
Company Info
Charles River Laboratories International, Inc. (CRL) had its IPO on 2000-06-23, and is trader on NYSE stock exchange.
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
CRL website: https://www.criver.com
